Last 12 months
Inside the activity.
1 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 1 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 29, 2016 Filed Jun 7, 2017 21:43 UTC |
Fortress Biotech, Inc.10% owner
|
GrantCommon Stock, $0.0001 par value | 15,806 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-031582 · v467961_form4.xml · nonDerivative · entry 5 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,150,370 F1 · kind: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing. Read SEC document |
| December 12, 2016 Filed Jun 7, 2017 21:43 UTC |
Fortress Biotech, Inc.10% owner
|
GrantCommon Stock, $0.0001 par value | 11,925 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-031582 · v467961_form4.xml · nonDerivative · entry 4 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,134,564 F1 · kind: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing. Read SEC document |
| November 30, 2016 Filed Jun 7, 2017 21:43 UTC |
Fortress Biotech, Inc.10% owner
|
GrantCommon Stock, $0.0001 par value | 47,505 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-031582 · v467961_form4.xml · nonDerivative · entry 3 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,122,639 F1 · kind: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing. Read SEC document |
| October 25, 2016 Filed Jun 7, 2017 21:43 UTC |
Fortress Biotech, Inc.10% owner
|
GrantCommon Stock, $0.0001 par value | 27,264 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-031582 · v467961_form4.xml · nonDerivative · entry 2 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,075,134 F1 · kind: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing. Read SEC document |
| September 30, 2016 Filed Jun 7, 2017 21:43 UTC |
Fortress Biotech, Inc.10% owner
|
GrantCommon Stock, $0.0001 par value | 47,870 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-031582 · v467961_form4.xml · nonDerivative · entry 1 Fortress Biotech, Inc. · CIK 0001429260 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,047,870 F1 · kind: The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of an equity financing. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.